Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.

Afisi S IsmailaNancy RisebroughMelanie SchroederDhvani ShahAlan A Martin Emma C GoodallKerigo NdiranguGerard CrinerMark DransfieldDavid Mg HalpinMeiLan K HanDavid A Lomas

Published in: International journal of chronic obstructive pulmonary disease (2019)

Treatment with FF/UMEC/VI was predicted to improve outcomes and be a cost-effective treatment option for patients with symptomatic COPD and a history of exacerbations compared with FF/VI or UMEC/VI, in Canada.

Keyphrases

chronic obstructive pulmonary disease
clinical trial
lung function
randomized controlled trial
cystic fibrosis
stem cells
type diabetes
study protocol
physical activity
metabolic syndrome
adipose tissue
phase iii
air pollution
double blind